Solid Biosciences IncNASDAQ:SLDB
- LAST PRICE5.7000
- TODAY'S CHANGE (%)0.0100 (0.1757%)
- Bid / Lots5.5000/ 1
- Ask / Lots6.2000/ 4
- Open / Previous Close5.7100 / 5.6900
- Day Range
- 52 Week Range
- Volume62,337
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLDB |
|---|---|---|
| 09:32 ET | 1059 | 5.71 |
| 09:33 ET | 500 | 5.762 |
| 09:35 ET | 500 | 5.78 |
| 09:37 ET | 500 | 5.78 |
| 09:42 ET | 200 | 5.72 |
| 09:44 ET | 2450 | 5.6649 |
| 09:48 ET | 850 | 5.66 |
| 09:55 ET | 1377 | 5.735 |
| 09:57 ET | 200 | 5.71 |
| 10:11 ET | 200 | 5.7159 |
| 10:20 ET | 3199 | 5.68 |
| 10:22 ET | 600 | 5.6622 |
| 10:26 ET | 444 | 5.668 |
| 10:27 ET | 200 | 5.63 |
| 10:29 ET | 100 | 5.64 |
| 10:31 ET | 314 | 5.64 |
| 10:33 ET | 854 | 5.656 |
| 10:38 ET | 2199 | 5.6 |
| 10:40 ET | 1000 | 5.6 |
| 10:44 ET | 4140 | 5.61 |
| 10:49 ET | 100 | 5.64 |
| 10:54 ET | 829 | 5.66 |
| 10:56 ET | 435 | 5.67 |
| 10:58 ET | 1000 | 5.68 |
| 11:00 ET | 285 | 5.695 |
| 11:03 ET | 1000 | 5.7 |
| 11:09 ET | 2088 | 5.67 |
| 11:12 ET | 133 | 5.67 |
| 11:18 ET | 100 | 5.64 |
| 11:25 ET | 100 | 5.65 |
| 11:30 ET | 100 | 5.6689 |
| 11:57 ET | 400 | 5.655 |
| 11:59 ET | 1305 | 5.655 |
| 12:01 ET | 300 | 5.655 |
| 12:03 ET | 500 | 5.65 |
| 12:08 ET | 500 | 5.649 |
| 12:10 ET | 731 | 5.65 |
| 12:12 ET | 329 | 5.64 |
| 12:17 ET | 200 | 5.63 |
| 12:21 ET | 200 | 5.66 |
| 12:24 ET | 200 | 5.665 |
| 12:26 ET | 100 | 5.665 |
| 12:32 ET | 100 | 5.67 |
| 12:39 ET | 600 | 5.6965 |
| 12:44 ET | 200 | 5.7 |
| 12:46 ET | 100 | 5.71 |
| 12:50 ET | 1300 | 5.735 |
| 12:51 ET | 500 | 5.71 |
| 12:53 ET | 675 | 5.72 |
| 12:55 ET | 348 | 5.71 |
| 12:57 ET | 2983 | 5.685 |
| 01:00 ET | 9429 | 5.7 |
Nov 26, 2024
Solid Biosciences to Participate at Upcoming Investor Conferences, from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
Nov 14, 2024
Solid Biosciences to Present at the Jefferies London Healthcare Conference, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
DJ Solid Biosciences Is Maintained at Overweight by JP Morgan, from 11:09AM ET on Tuesday Nov 12, 2024 by Dow Jones
11:09AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
DJ Solid Biosciences Is Maintained at Buy by Chardan Capital, from 4:59PM ET on Monday Nov 11, 2024 by Dow Jones
4:59PM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
DJ Solid Biosciences Price Target Maintained With a $16.00/Share by HC Wainwright & Co., from 6:27AM ET on Thursday Nov 07, 2024 by Dow Jones
6:27AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Solid Biosciences Inc | 230.9M | -1.9x | --- |
Acrivon Therapeutics Inc | 234.1M | -2.8x | --- |
Benitec Biopharma Inc | 225.9M | -1.9x | --- |
DiaMedica Therapeutics Inc | 222.8M | -10.2x | --- |
Tevogen Bio Holdings Inc | 239.8M | 3.5x | --- |
Kyverna Therapeutics Inc | 218.4M | -2.3x | --- |
Company Information
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Contact Information
- Headquarters
- 500 RUTHERFORD AVENUE, 3RD FLOORCHARLESTOWN, MA, United States 02129
- Phone
- 617-337-4680
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Ian Smith
- President, Chief Executive Officer, Director
- Alexander Cumbo
- Co-Founder, Director
- Ilan Ganot
- Chief Financial Officer, Treasurer
- Kevin Tan
- Chief Operating Officer, General Counsel, secretary
- David Howton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $230.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 40.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.01 |
EPS | $-3.04 |
Book Value | $6.20 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
